AstraZeneca at TPD Summit 2026

Oct 26–29, 2026 Boston, MA ~300 attendees Website

AstraZeneca takes part in 2 sessions at TPD Summit 2026 in Boston. Its sessions cover how molecular glue binding kinetics relate to performance, using quantitative modelling, and AURKB PROTACs designed as a new payload class for degrader-antibody conjugates.

OrganizationTPD Summit 2026 Attendance
AstraZeneca
Cambridge, UK
astrazeneca.com
Large pharma
Global pharmaceutical company developing medicines in oncology, cardiovascular, renal, respiratory, immunology and rare diseases.
Talk
Wed Oct 28
2:30pm
Linking Molecular Glue Binding Kinetics to Functional Performance Through Quantitative Modeling
Track A: Discovery
AI & computational design
Talk
Thu Oct 29
9:30am
Developing AURKB PROTACs as a Novel Payload Class for Next-Generation Degrader Antibody Conjugates (DACs)
Future of Induced Proximity Track
Degrader conjugates & tissue targeting

Explore the full TPD Summit 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full TPD Summit 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from AstraZeneca

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the TPD & Induced Proximity Summit or its organizers. Submit a correction